Dr. Rajesh Shukla, Vice President Research and Development at Seqens Talks about Controlling Impurities during API drug manufacturing.
Related posts:
Four Keys to Optimizing Process Research
Do's and Don'ts of API Technology Transfer in Phases 1, 2 and 3 Clinical Trials
7 things to look for in a CMO’S CGMP Manufacturing Capabilities
Massachusetts Maintains Status as Leading Life Sciences Hub
How Sponsors and CDMOs are Preparing to Manufacture APIs for Complex Generic 3 Criteria for picking ...